Monopar Therapeutics Inc. (MNPR) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street rises on revived AI momentum as earnings season picks up
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts MNPR Hot Sheet
Join SI Premium – FREE
Monopar Therapeutics Inc. (NASDAQ: MNPR) reported Q4 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21).
For earnings history and earnings-related data on Monopar Therapeutics Inc. (MNPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GM to offer hybrid versions of top-selling SUV models - report
- PACCAR (PCAR) Reports In-Line Q3 EPS
- Top E&C stocks to watch ahead of Q3 earnings, says Citi
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
